Article Text

other Versions

PDF
Axonal Guillain–Barré syndrome is underestimated in Europe?
  1. S Kuwabara
  1. Department of Neurology, Graduate School of Medicine, Chiba University, Japan
  1. Correspondence to Satoshi Kuwabara, Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan; kuwabara-s{at}faculty.chiba-u.jp

Statistics from Altmetric.com

The concept of Guillain–Barré syndrome (GBS) largely changed in the 1990s, because acute motor axonal neuropathy (AMAN), an axonal subtype of GBS, was recognized. Neurophysiological, pathological and immunological observations have shown that GBS is currently divided into two major subtypes, acute inflammatory demyelinating polyneuropathy (AIDP; a classical demyelinating form) and AMAN.1

Before recognition of AMAN, the eponym GBS has been used interchangeably with AIDP, and it has been believed that in Europe and North America, GBS is usually caused by AIDP, which accounts for >90% of GBS cases.1 In contrast, a considerable number of GBS patients have AMAN in East Asia such as …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles